The latest research by Leivonen and colleagues [109] demonstrated how higher expression of miR-342-5p, which is an efficient negative regulator of the HER2 pathway, was significantly associated with better survival in two heterogeneous breast cancer cohorts. This evidence concerns the gene ERBB2 and breast carcinoma.